Key Findings:  This study of the CB2-selective agonists O-1966, using Mixed Lymphocyte Reaction (MLR) on mice spleen cells as a model of transplant rejection, found that the compound effectively prevented or delayed graft rejection and presents a potential novel therapeutic target in graft-versus-host disease in transplant recipients.
Type of Study:  Laboratory Study
Study Result:  Positive
Study Location(s):  United States
Year of Pub:  2016
Cannabinoids Studied:  Tetrahydrocannabinol (THC), O-x Synthetic Cannabinoids, Endocannabinoid (unspecified)
Phytocannabinoid Source:  Not Applicable
Receptors Studied:  CB1, CB2
Ligands Studied:  Anti-inflammatory cytokines